# A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

> **NCT05838755** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 147 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** GSK3858279
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05838755
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-20
- **Primary completion:** 2024-10-14
- **Final completion:** 2025-02-17
- **Target enrollment:** 147 (ACTUAL)
- **Why stopped:** The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05838755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05838755, "A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05838755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*